Vaccines against Francisella tularensis--past, present and future
- PMID: 15176947
- DOI: 10.1586/14760584.3.3.307
Vaccines against Francisella tularensis--past, present and future
Abstract
Francisella tularensis is a facultative intracellular bacterial pathogen capable of causing a spectrum of human diseases collectively called tularemia. The pathogen is highly infectious and some strains can cause rapidly lethal infection especially when inhaled. The latter were developed as biological weapons in the past and nowadays cause concern as potential bioterrorism agents. A live attenuated strain of the pathogen was developed more that 40 years ago and remains the sole prophylactic measure against the pathogen. Research to develop better live and subunit vaccines is under way. The former will require an understanding of the virulence factors of F. tularensis and a facile means of mutating them and the latter will require identification of the protective antigens of the pathogen. The current vaccine and its potential replacements are the focus of this review.
Similar articles
-
Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.Vaccine. 2005 Mar 31;23(19):2477-85. doi: 10.1016/j.vaccine.2004.10.034. Vaccine. 2005. PMID: 15752834
-
Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent F. tularensis subsp. tularensis.Front Cell Infect Microbiol. 2018 May 15;8:154. doi: 10.3389/fcimb.2018.00154. eCollection 2018. Front Cell Infect Microbiol. 2018. PMID: 29868510 Free PMC article. Review.
-
Tularemia vaccines: recent developments and remaining hurdles.Future Microbiol. 2011 Apr;6(4):391-405. doi: 10.2217/fmb.11.22. Future Microbiol. 2011. PMID: 21526941 Review.
-
Vaccines against tularemia.Hum Vaccin. 2009 Dec;5(12):832-8. doi: 10.4161/hv.10297. Epub 2009 Dec 11. Hum Vaccin. 2009. PMID: 19923904 Free PMC article. Review.
-
Live attenuated tularemia vaccines: recent developments and future goals.Vaccine. 2013 Aug 2;31(35):3485-91. doi: 10.1016/j.vaccine.2013.05.096. Epub 2013 Jun 10. Vaccine. 2013. PMID: 23764535 Free PMC article. Review.
Cited by
-
Immunoproteomic analysis of the human antibody response to natural tularemia infection with Type A or Type B strains or LVS vaccination.Int J Med Microbiol. 2011 Nov;301(7):591-601. doi: 10.1016/j.ijmm.2011.07.002. Epub 2011 Aug 27. Int J Med Microbiol. 2011. PMID: 21873113 Free PMC article.
-
Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters.NPJ Vaccines. 2021 Mar 30;6(1):47. doi: 10.1038/s41541-021-00321-8. NPJ Vaccines. 2021. PMID: 33785745 Free PMC article.
-
Control of Francisella tularensis Intracellular Growth by Pulmonary Epithelial Cells.PLoS One. 2015 Sep 17;10(9):e0138565. doi: 10.1371/journal.pone.0138565. eCollection 2015. PLoS One. 2015. PMID: 26379269 Free PMC article.
-
Identification of a live attenuated vaccine candidate for tularemia prophylaxis.PLoS One. 2013 Apr 17;8(4):e61539. doi: 10.1371/journal.pone.0061539. Print 2013. PLoS One. 2013. PMID: 23613871 Free PMC article.
-
Glycoconjugate vaccine using a genetically modified O antigen induces protective antibodies to Francisella tularensis.Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7062-7070. doi: 10.1073/pnas.1900144116. Epub 2019 Mar 14. Proc Natl Acad Sci U S A. 2019. PMID: 30872471 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous